Jubilant

UKG Partners of the Year Help Create Great Workplaces

Retrieved on: 
Wednesday, March 13, 2024
Software, Human Resources, Internet, Artificial Intelligence, Data Management, Professional Services, Technology, Apps, Applications, Cloud, UKG, Automation, Certification, Partner, HR, Culture, IVR, Organization, Communication, Partnership, Strategic planning, Acquisition, Investment, HCM, PayActiv, Vertex, Workforce, Accenture, Workplace, Jubilant, G2, Work

“Highly extensible technology, a deep understanding of culture, and the collaborative spirit of our entire partner network help customers keep workplaces centered on people, not processes.”

Key Points: 
  • “Highly extensible technology, a deep understanding of culture, and the collaborative spirit of our entire partner network help customers keep workplaces centered on people, not processes.”
    Each year, UKG recognizes partners for going above and beyond in their efforts to create exceptional experiences for UKG customers and their employees.
  • This includes technology partners that deliver new innovations or extensible solutions that enhance IT experiences, and services partners that implement UKG suites as a cornerstone of culture and workplace transformations.
  • The UKG 2023 Technology and Services Partners of the Year:
    Innovator of the Year recognizes partners that showcase innovative technology, creative solutions, and strategic planning and execution for joint customers.
  • Technology Partner Recipient: CloudApper , for its suite of generative AI, no-code, and low-code tools that help UKG customers quickly create apps and integrations.

MedPharm, Ltd. Appoints Lynn Allen as Chief Executive Officer

Retrieved on: 
Thursday, January 18, 2024
CDMO, Jubilant, Laboratory, Business development, Management

GUILDFORD, England and DURHAM, N.C., Jan. 18, 2024 /PRNewswire/ -- MedPharm, a global topical and transdermal CDMO, announced today that Lynn Allen has been named Chief Executive Officer (CEO), effective January 1, 2024.

Key Points: 
  • GUILDFORD, England and DURHAM, N.C., Jan. 18, 2024 /PRNewswire/ -- MedPharm, a global topical and transdermal CDMO, announced today that Lynn Allen has been named Chief Executive Officer (CEO), effective January 1, 2024.
  • Ms. Allen has more than 25 years of experience in contract development and manufacturing services specific to topical, transdermal, and injectable delivery routes.
  • Prior to joining MedPharm in 2019 as Vice President of Business Development, Ms. Allen held a series of commercial leadership roles at DPT Laboratories and Jubilant HollisterStier.
  • "I am honored to have the opportunity to serve as CEO alongside the expertise and support of the entire leadership team at MedPharm," said Ms. Allen.

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

Retrieved on: 
Wednesday, October 18, 2023
Jubilant, GE HealthCare, Vice, Premier Medical Group, Business development, Growth, Novartis, Interim, Radioimmunotherapy, Cancer, Therapy, Patient, Management, Nursing

“Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.

Key Points: 
  • “Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.
  • “We are extremely grateful for Thomas’s successful leadership and dedication as Interim CEO.
  • We look forward to Thomas’s continued leadership in his new role as Vice Chairman of the Board of Directors and Chief Business Officer of Y-mAbs.”
    Mr. Rossi said, “I have long admired Y-mAbs as a leader in the development of transformative cancer therapies.
  • Y-mAbs is a pioneer in pretargeted radioimmunotherapy with its SADA Technology and diverse pipeline of promising SADA programs, and a science-driven, patient-first culture.

Jubilant Radiopharma and Cardiac Imaging, Inc. Announce Exclusive Partnership to Expand Access for Mobile Cardiac PET Offering

Retrieved on: 
Friday, September 29, 2023
Hospitals, Health, Radiology, Pharmaceutical, Cardiology, Learning, Cardiac imaging, ASNC, Partnership, Cardiac PET, CAD, PET, Westin Harbour Castle Hotel, Patient, Physician, Society, Heart, Hospital, Jubilant

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

Key Points: 
  • Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
  • “This partnership with Cardiac Imaging allows unprecedented access of RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) to various types of facilities interested in performing cardiac PET,” said Sergio Calvo, President, Jubilant Radiopharma, Radiopharmaceuticals Division.
  • Cardiac Imaging, Inc.’s fixed site program is a comprehensive turnkey offering, enabling physicians to administer Cardiac PET in their own facilities.
  • Through these solutions, Cardiac Imaging, Inc. is advancing the field of cardiac PET and delivering premier cardiac care across the US.

Ian Fuller Named Vice President of Operations at Jubilant HollisterStier Contract Manufacturing

Retrieved on: 
Thursday, September 14, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Manufacturing operations, Dexcom, Jubilant, Multimedia, Real estate, CMO, Mylan, Engineering, Management, Operation

Jubilant HollisterStier Contract Manufacturing is pleased to announce the appointment of Ian Fuller as the new Vice President of Operations.

Key Points: 
  • Jubilant HollisterStier Contract Manufacturing is pleased to announce the appointment of Ian Fuller as the new Vice President of Operations.
  • View the full release here: https://www.businesswire.com/news/home/20230914848840/en/
    Ian Fuller, Vice President of Operations at Jubilant HollisterStier Contract Manufacturing.
  • His recent positions include Senior Director of Global Facilities and Real Estate at Dexcom and Vice President of Manufacturing Operations at Mylan.
  • "I am excited about the challenges and the journey ahead and look forward to contributing to Jubilant HollisterStier's advancement in the CMO industry," commented Mr. Fuller.

Kansas City Based Digital Agency, Jubilant Digital Marketing, Earns Place on the 2023 Inc. 5000

Retrieved on: 
Tuesday, August 15, 2023
Advertising, Marketing, Jubilant, SEO, Heel, CRM, United Group for Publishing Advertising and Marketing, Growth, Digital, Automation, Video game, Cryptocurrency

OVERLAND PARK, Kan., Aug. 15, 2023 /PRNewswire-PRWeb/ -- Jubilant Digital Marketing is thrilled to announce it has been awarded a place in the Inc. 5000 for being one of the fastest-growing companies in the nation, with three-year revenue growth of 135%. Jubilant has also been named among the top 500 companies in Advertising and Marketing and the top 50 in Kansas City.

Key Points: 
  • Jubilant has also been named among the top 500 companies in Advertising and Marketing and the top 50 in Kansas City.
  • Jubilant has also been named among the top 500 companies in Advertising and Marketing and the top 50 in Kansas City.
  • The Inc. 5000 award lists the top 5,000 fastest-growing private companies in the United States based on revenue growth rate.
  • The Inc. 5000 comes on the heels of several other accolades for the Kansas City-based digital marketing company, including multiple Web Excellence awards.

Jubilant Digital Marketing Adds First Partner to Organization

Retrieved on: 
Thursday, June 29, 2023
Growth, Digital, Swiss Army knife, Life, Marketing, Management, Cryptocurrency, Jubilant

OVERLAND PARK, Kan., June 29th, 2023 /PRNewswire-PRWeb/ -- Jubilant is excited and pleased to announce its newest Partner, Morgan Nielsen. Morgan's experience, leadership and dedication to serving clients at Jubilant Digital have made her a perfect candidate for this promotion to Vice President of Brand Strategy.

Key Points: 
  • OVERLAND PARK, Kan., June 29th, 2023 /PRNewswire-PRWeb/ -- Jubilant is excited and pleased to announce its newest Partner, Morgan Nielsen.
  • Josh Eliseuson, Founder and Digital Strategist at Jubilant Digital, looks forward to having Morgan onboard as his partner.
  • "She is truly the Swiss Army Knife of digital marketing and has been an integral part of our growth."
  • With Morgan's expertise in the digital marketing sector, Jubilant Digital has grown exponentially and has been able to offer a new diverse suite of services.

Jubilant Radiopharma Introduces RUBY Mobile Solutions™

Retrieved on: 
Friday, June 23, 2023
Cardiology, Radiology, Biotechnology, Practice Management, Pharmaceutical, Health, FDA, Hospitals, Learning, Society, Society of Nuclear Medicine and Molecular Imaging, PET, Jubilant, Hospital, Patient, McCormick Place, Coronary artery disease, Rest, Medical device

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) in mobile settings.

Key Points: 
  • Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) in mobile settings.
  • Since the FDA approval of RUBY-FILL in 2016, Jubilant Radiopharma has partnered with health care providers across the U.S. to establish and grow cardiac PET programs.
  • “The approval for mobile use with RUBY-FILL for cardiac PET is another example of Jubilant Radiopharma’s ongoing commitment to expand this imaging modality and increase patient access to this crucial test”, said Sergio Calvo, President, Jubilant Radiopharma, Radiopharmaceuticals Division.
  • Additionally, if you are interested in starting a full or part time cardiac PET program, or are interested in learning more about Jubilant Radiopharma’s “RUBY Mobile Solutions” program, please visit www.RUBY-FILL.com

James Kaufman appointed as Chief Commercial Officer at Serac Imaging Systems, the developer of Seracam®

Retrieved on: 
Tuesday, June 20, 2023
Ohio State University, GE HealthCare, Marketing, Journal of Nuclear Medicine Technology, Jubilant, Public key certificate, Business administration, Molecular imaging, Cardiology, Neurology, Global Sales Law Project, Medical imaging, Science, Ashland University

LONDON, June 20, 2023 /PRNewswire/ -- Serac Imaging Systems Limited ("Serac Imaging Systems" or "the Company"), the medical technology company developing Seracam®, a portable hybrid gamma-optical camera for medical imaging, today announces the appointment of James Kaufman as Chief Commercial Officer.

Key Points: 
  • LONDON, June 20, 2023 /PRNewswire/ -- Serac Imaging Systems Limited ("Serac Imaging Systems" or "the Company"), the medical technology company developing Seracam®, a portable hybrid gamma-optical camera for medical imaging, today announces the appointment of James Kaufman as Chief Commercial Officer.
  • James brings almost thirty years' experience in the global healthcare and molecular imaging industry and will be responsible for leading on the commercialisation of Seracam®, reporting to Chief Executive, Mark Rosser.
  • James (Jim) joins from Jubilant Radiopharma where he served as the Vice President of Global Sales.
  • He received his Nuclear Medicine Technology training at The Ohio State University and is Board Certified in Nuclear Medicine Technology.

Jubilant Therapeutics Inc. Appoints Nadir Patel as an Independent Member of Its Board of Directors

Retrieved on: 
Thursday, June 15, 2023
Ambassador, HEC, Therapy, Accreditation, Rotman School of Management, Trade and development, Consul, Foreign Affairs, MBA, Ministry of Foreign Affairs, Strategic planning, Jubilant, Assistant, Development, Republic, School, New York University Stern School of Business, Canadian Tire, High commissioner, Kingdom, Charitable organization, Titan Tire Corporation, G3 (company), London School of Economics, Management, Economics

BEDMINSTER, N.J., June 15, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc ., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the appointment of Nadir Patel as an independent director on the Company's Board of Directors.

Key Points: 
  • BEDMINSTER, N.J., June 15, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc ., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the appointment of Nadir Patel as an independent director on the Company's Board of Directors.
  • Prior to his current roles, Nadir held several senior government positions over a notable career in Canada's public service.
  • He currently serves on the board of directors of Canadian Tire Corporation where he also chairs the audit committee, as well as board Chairman at Canadian Tire Jumpstart Charities.
  • Nadir Patel holds a joint MBA from New York University's Stern School of Business, London School of Economics and Political Science, and HEC (Paris) School of Management.